Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.
ADMA
$8.62
-$0.25 -2.87%

ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.

Market News
20 Apr 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud following a 29% drop in its stock price. The plunge was triggered by a report from Culper Research accusing the company of channel stuffing to inflate its 2025 revenue growth from an actual decline of 3% to a reported 20%. This alleged scheme involved pushing excess product to distributors with incentives to meet sales targets. Investors who bought ADMA shares are encouraged to seek legal advice as the investigation continues.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App